 CHARLESTON, S.C., June 03, 2021 GLOBE NEWSWIRE -- Aeterna Zentaris Inc. NASDAQ: AEZS TSX: AEZS Aeterna or the Company, a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced the U.S. District Court for the District of New Jersey has given final approval of the settlement from the previously disclosed class-action lawsuit against the Company. The settlement payment will be funded entirely by the Companys insurers. Pending no action taken during the 30-day appeal period, this matter will be considered fully and finally settled. 